|
|
LIDOCAIN
-
| StockNo |
Product description |
| EB0280-418-06 |
LIDOCAIN
AMPOULE 40MG/2ML 2% SOLUTION |
| EB0280-418-19 |
LIDOCAIN
AMPOULE 50MG/10ML 0.5% SOLUTION |
| EB0280-418-20 |
LIDOCAIN
AMPOULE 100MG/10ML 1% SOLUTION |
| EB0280-418-21 |
LIDOCAIN
AMPOULE 200MG/10ML 2% SOLUTION |
-
- COMPOSITION:
Lidocaine hydrochloride 40 mg/2 ml; 20 mg/10 ml;
100 mg/10 ml and 200 mg/10 ml in one ampoule
ACTION:
Lidocain is a synthetic local anaesthetic which guarantees a fast
and long-lasting analgesic effect. Its anaesthetic effect is twice
stronger and twice longer (up to 75 min) compared to procain. It
demonstrates an antiarrhythmic and analgesic activity, without
acting as a local irritant. Parenteral administration results
quickly in therapeutic concentrations in the patient's blood
(occurring immediately after intravenous injection and 5-15 min
after intramuscular injection). Lidocain binds with the blood plasma
proteins at an average rate of 60%, after which it undergoes a rapid
biotransformation in the liver. Its antiarrhythmic effect is
selective and is due to accelerated repolarization, decrease of the
second phase of the transmembrane potential and potentiation of the
potassium efflux.
INDICATIONS:
The injection solution is used for pain relief during various
surgical, gynecological, stomatological, urological,
ophthalmological and oto-rhino-laringological interventions.
In cardiological practice it is used for treatment and prevention of
rhythmic disturbances of a venticular nature, including venticular
fibrillations in patients with myocardial infarction.
CONTRAINDICATIONS:
Severe myasthenia, cardiovascular and liver insufficiency, as well
as for patients subjected to quinidine therapy. It is administered
with caution in cases of disturbances in the renal functions and
hypersensitivity to local anaesthetics.
SIDE EFFECTS:
Vision disturbances, allergic reactions and decreasing of the blood
pressure after fast administration. Overdosing might cause pallour,
nausea, vomiting, vascular collapse, suppression of the respiratory
center, convulsions and methemoglobinemia. |
DRUG INTERACTIONS:
It is not advisable to combine this drug with beta-adrenergic
blockers, because it might result in bradycardia, hypotension and
bronchial spasm; with digitoxin because it will weaken its
cardiotonic effect; with curare-like drugs due to the increased
muscle relaxation caused by them, which might lead to paralysis of
the respiratory muscles.
PRECAUTIONS:
Lidocain in low concentrations has a low toxicity, but its toxicity
increases in a geometric progression when the dose is raised, hence
minimal effective concentrations should be used.
In order to prevent hypotension and collapse, which might occur
after parenteral administration of lidocain, it is possible to
inject 1 ml 5 % ephedrine solution in advance.
DOSAGE AND ADMINISTRATION:
Injection solution:
Infiltrative anaesthesia is usually achieved by using 0.5% solution
together with 1% adrenaline solution (2 drops per 10 ml), the dose
needed for minor surgical interventions being 2 to 50 ml and up to
100 ml for major surgery. For conduction anaesthesia - 1 % and 2 %
lidocain solution is used, for epidural anesthesia - 0.5 % and 1 %
solution in quantities of 20 to 30 ml. Surface anaesthetic effect
for mucosa and skin may be obtained by using 1 % and 2 % lidocain.
The maximum amount of anaesthetic used should not exceed 500 ml for
the 0.5 % solution and 250 ml for the 1 % solution. In the case of
arrhythmias, especially in ventucular extrasystolic states, 10-20 ml
of 1 % solution and 4-6 ml of 2 % solution are administered
intravenously, or in the form of drop infusion of 1-4 mg/ min in 5 %
glucose solution. The infusions are repeated, if necessary, until
the desired therapeutic effect is achieved.
MEDICINAL FORM AND PACKAGE:
Packages with 10 and 50 ampoules of 40 mg/ 2 ml (2 %); 50 mg/10 ml
(0.5 %); 100 mg/10 ml (1 %) and 200 mg/10 ml (2 %).
STORAGE:
At moderate temperature (15-30° C).
EXPIRY:
5 (five) years.
|
|
|
